Baker Bros. Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Baker Bros. Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-46,750	Closed	-$3.34M	–	121
2018 Q2	$3.34M	Hold	46,750	–	–	0.03%	88
2018 Q1	$2.87M	Hold	46,750	–	–	0.02%	87
2017 Q4	$5.89M	Hold	46,750	–	–	0.05%	72
2017 Q3	$6.39M	Buy	+46,750	New	+$6.25M	0.05%	70

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baker Bros. Advisors's TTPH Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2018, closing a stake of 46,750 shares — an estimated $3.34M sold.

Baker Bros. Advisors first reported a position in TTPH in Q3 2017 and held it in 4 quarters. The position peaked at $6.39M in Q3 2017. 92 funds tracked by Wall St. Rank hold TTPH as of Q3 2018.

Baker Bros. Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Baker Bros. Advisors sold 46,750 Tetraphase Pharmaceuticals, Inc. shares in Q3 2018, an estimated $3.34M.
Baker Bros. Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q3 2017 and held it in 4 quarters.
Baker Bros. Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $6.39M in Q3 2017.
92 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.